Yu Wei, Guo Xiaodong
Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China.
Arch Osteoporos. 2017 Dec;12(1):15. doi: 10.1007/s11657-017-0311-x. Epub 2017 Feb 2.
Management of fracture nonunion is challenging as another surgical intervention for the patient is often a necessity, which has a huge impact on both quality of life and economic burden of the patient. Thus, a less aggressive and better accepted treatment for nonunion is required.
We gave teriparatide to a 45-year-old man with femoral fracture nonunion 1 year after he underwent surgery with autogenous bone grafting that failed to heal his initial nonunion. Successful union was obtained after once-daily administration of teriparatide for 9 months.
Our case showed teriparatide could successfully treat a femoral fracture nonunion that autogenous bone grafting failed to heal.
Teriparatide may provide an alternative treatment for fracture nonunion.
骨折不愈合的治疗具有挑战性，因为往往需要对患者进行再次手术干预，这对患者的生活质量和经济负担都有巨大影响。因此，需要一种侵入性较小且更容易被接受的不愈合治疗方法。
我们对一名45岁的男性股骨骨折不愈合患者使用了特立帕肽，该患者在接受自体骨移植手术后1年仍未愈合，最初的不愈合情况未得到改善。每天一次注射特立帕肽9个月后，实现了骨折成功愈合。
我们的病例显示，特立帕肽能够成功治疗自体骨移植未能治愈的股骨骨折不愈合。
特立帕肽可能为骨折不愈合提供一种替代治疗方法。
